CME

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Host: Perry B. Shieh, MD, PhD

Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.

Host: Jennifer Caudle, DO

Guest: Patricia A. Mangan, RN, MSN, APRN-BC

The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.

Host: Leslie Citrome, MD, MPH

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

Host: Christoph U. Correll, MD

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

Host: Jessica S. Donington, MD, MSCR

This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of neoadjuvant and adjuvant chemoimmunotherapy while gaining critical knowledge to improve patient outcomes through collaborative, evidence-based care.

Host: Mark Awad, MD, PhD

This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of neoadjuvant and adjuvant chemoimmunotherapy while gaining critical knowledge to improve patient outcomes through collaborative, evidence-based care.

Host: Mark Awad, MD, PhD

Host: Jessica S. Donington, MD, MSCR

This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of neoadjuvant and adjuvant chemoimmunotherapy while gaining critical knowledge to improve patient outcomes through collaborative, evidence-based care.